The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose DeprivationDina Baier, Walter Berger|Pharmaceutics|2022Cited by 37
The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone AcetylationDina Baier, Walter Berger|Advanced Science|2023Cited by 21